Neoadjuvant and postneoadjuvant treatment for triple negative breast cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Triple negative cancer is a subtype of breast cancer (BC) characterized by the absence of the expression of estrogen and progesterone receptors, and the absence of HER2 overexpression and amplification. Triple negative breast cancer (TNBC) accounts for 10-20% of all breast cancer cases, and is somewhat more common in young patients compared to hormone receptor-positive disease and is characterized by a more aggressive course and early relapses. Despite the mass of studies on this topic, only chemotherapy remains the standard of treatment for this disease due to the absence of any targets on the surface of the tumor available for action. Taking into account the aggressiveness of the disease, many attempts are being made to improve the treatment outcomes of patients with TNBC. They include the use of post-neoadjuvant therapy, the addition of platinum supplements, the use of dose-dense regimens, the use of PARP inhibitors, and the search for various biomarkers to identify patients to whom additional therapies could be applied. This review represents the results of modern trials on these issues.

Full Text

Restricted Access

About the authors

V. F Semiglazov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

Maryam A. Dzhelyalova

N.N. Petrov National Medical Research Center of Oncology

Email: gub.mariam@gmail.com
Oncologist, Clinical Diagnostic Department 68, Leningradskaya str., Pesochny settlement, St. Petersburg 197758, Russian Federation

A. I Tseluyko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

R. S Pesotsky

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. A Bessonov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

T. Yu Semiglazova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

References

  1. Masuda N., Lee S.J., Ohtani S., et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147-59. doi: 10.1056/NEJMoa1612645.
  2. Kuroi K, Toi M., Ohno S., et al. Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG. Breast Cancer. 2015;22:486-95. https://doi.org/10.W07/s12282-013-0511-1
  3. Twelves C., Wong A., Nowacki M.P, et al. Capecitabine as Adjuvant Treatment for Stage III Colon Cancer N Engl J Med. 2005;352:2696-704. Doi: 10.1056/ NEJMoa043116.
  4. Bang YJ., Kim Y.W., Yang H.K., et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2019(989(9813):-15-21.doi: 10.1016/S0140-6736(11)61873-4.
  5. Noh S.H., Park S.R., Yang H.K., et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet. Oncol. 2014;15(12):1389-96. doi: 10.1016/S1470-2045(14)70473-5.
  6. Martin M, Ruiz S.A., Ruiz B.M., et al. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2000-10 Study. J Clin Oncol. 2015;33(32):3788-95. Doi: 10.1200/ JCO.2015.61.9510.
  7. Joensuu H., Kellolumpu-Lehtinen P.L., Huovinen R., et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol. 2012;30(1):11-8. Doi: 10.1200/ JCO.2011.35.4639.
  8. Blum J.L., Jones S.E., Buzdar A.U., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17(2):485-93. Doi: 10.1200/ JCO.1999.17.2.485.
  9. Miles D., von Minckwitz G., Seidman A.D., et al. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist. 2002;7(Suppl. 6):13-9.
  10. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2006;055:2700-40. doi: 10.1056/NEJMoa064320.
  11. O'Shaughnessy J., Koeppen H., Xiao Y, et al. Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clin. Cancer Res. 2015;21(19):4305-11. doi: 10.1158/1078-0432. CCR-15-0636.
  12. Masuda N., Lee S.J., Ohtani S., et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147-59. doi: 10.1056/NEJMoa1612645.
  13. Toi M., Atiqur Rahman М., Bando H., Chow L.W. Thymidine phosphorylase (plateletderived endothelialcell growth factor) in cancer biology and treatment. Lancet. Oncol. 2005;6:158-66. Doi: 10.1016/ S1470-2045(05)01766-3.
  14. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemothe arable HER2-positive breast cancer. N Engl J Med. 2005;050:1670-84. doi: 10.1056/NEJMoa052122.
  15. Sparano J.A., Zhao R., Martino S., et al. Long-term follow-up of the Е 1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol. 2015;00:2050-60. Doi: 10.1200/ JCO.2015.60.9271.
  16. Moebus V, Jackisch С., Lueck H.J., et al. Intense no conflicts of interest. dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Oncol. 2010;28:2874-80. Doi: 10.1200/ JCO.2009.24.7643.
  17. Bear H.D., Tang G., Rastogi ft, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3 randomized controlled trial. Lancet. Oncol. 2015;16:1037-48. doi: 10.1016/S1470-2045(15)00041-8.
  18. von Minckwitz G., Rezai M., Loibl S., et al. Capecitabine in addition to anthracycline and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol. 2010;28:2015-23. Doi: 10.1200/ JCO.2009.23.8303.
  19. Ohno S., Chow L.W., Sato N., et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki-67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res. Treat. 2013;142(1):69-80. doi: 10.1007/s10549-013-2691-y.
  20. Cortazar P., Zhang L., Untch M., et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164-72. doi: 10.1016/S0140-6736(13)62422-8.
  21. Symmans W.R., Peintinger R., Hatzis C., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414-22. Doi: 10.1200/ JCO.2007.10.6823.
  22. Symmans W.R., Wei C., Gould R., et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and BreastCancer Subtype. J Clin Oncol. 2017;35:1049-doi: 10.1200/JCO.2015.63.W10. [Epub 2017 Jan 30].
  23. Denkert С., von Minckwitz G., Darb-Esfahani S., et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet. Oncol. 2018;19:40-50. Doi: 10.1016/ S1470-2045(17)30904-X.
  24. Luen S., Solgado R., Died M., et al. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple negative breast cancer patients after neoadjuvant chemotherapy. Ann Oncol. 2019;30(2):236-42. Doi: https://doi.org/10.1093/annonc/mdy547.
  25. Loi S., Dmbay D., Adams S., et al. Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapy. Cancer Res. 2016;76:Abstract S 1-03. Doi: 10.1200/ JCO.18.01010.
  26. Dieci M.V., Criscitiello C., Goubar A., et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25:611-823. doi: 10.1093/annonc/ mdt556.
  27. CrisctielJo С, Bny ar M.A., Curigliano G., et al. A gene signature to predict hightumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. Ann Oncol. 2018;29:162-69. doi: 10.1093/ annonc/mdx691.
  28. Haitmann L, Schaid D., Woods J., Crotty T., Myers J. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. Engl J Med. 1999;340(2):77-84. Doi: 10.1056/ NEJM199901143400201.
  29. Phillips K.A., Lindeman G.J. Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen? Future Oncol. 2014;10(4):499-502. doi.org/10.2217/fon.13.278
  30. Fisher В., Costantino J.P, Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 2005;97:1652-62. doi: 10.1093/jnci/dji372.
  31. Cuzick J., Sestak I., Bonanni B., et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual. Lancet. 2013;381(9880):1827-34. doi: 10.1016/S0140-6736(13)60140-3.
  32. Metcalfe K., Lynch H.T., Ghadirian P., et al. Contralateral breast cancer in BRCAl and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328-35. Doi: 10.1200/ JCO.2004.04.033.
  33. Narod S.A. Hormonal prevention of hereditary breast cancer. Ann N Y Acad Sci. 2001;952:36-43. Doi. org/10.1111/j.1749-6632.2001.tb02726.x
  34. Farmer H. McCabe N., Lord C.J., et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-21. https://doi.org/10.1038/nature03445
  35. Robson M., Im S.A., Senkus E., et al: Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523-33. doi: 10.1056/NEJMoa1706450.
  36. Litton J.K., Rugo H.S., Ettl J., et al: Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753-63. doi: 10.1056/NEJMoa1802905.
  37. Ettl J., Quek R.G.W., lee K.H., et al: Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial. Ann. Oncol. 2018;29:1939-47. doi: 10.1090/annonc/mdy257.
  38. Burstein H.L., Curigliano G., toibl S., et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;00(10):1541-57. Doi: 10.1093/ annonc/mdz235.
  39. Loibl S., Weber K.E., Timms K.M., et al. Survival analysis of carboplatin added to an anthracycline/taxanebased neoadjuvant chemotherapy and HRD score as predictor of responsefinal results from GeparSixto. Ann Oncol. 2018;29(12):2041-47. Doi: 10.1093/ annonc/mdy460.
  40. hoibl S., Untch M.N., et al. Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). J Clin Oncol 2018;36(suppl):abstr 104. doi: 10.1200/JCO.2018.36.15_suppl.104.
  41. Nanda R., Liu M.C., Yau C., et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (ВС): results from I-SPY2. J Clin Oncol. 2017;35(l5):S506-6. Doi: 10.1200/ JCO.2017.35.15_suppl.506.
  42. Martin M., Barrios C.H., Torrecilla L., et al. Efficacy results form the CIBOMA 2004-01/ GEICAM 200311 study: a randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer. SABCS. 2018. doi: 10.1158/1538-7445.SABCS18-GS2-04.
  43. Nitz U., Gluk O., Clegpens М., et al. West German PlanB Trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2 negative early breast cancer. J Clin Oncol. 2019;37:799-808. doi: 10.1200/JCO.18.00028.
  44. Blum J.L., Flynn PJ., Yothers G., et al. Anthracyclines in early breast cancer: the ABC Trials USOR 06-090, NSABP B-46-1/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017;35:2647-55. doi: 10.1200/JCO.2016.71.4147.
  45. Robson М., Im S.A., Senkus Е., et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523-33. doi: 10.1056/NEJMoa1706450.
  46. Weigelt В., Comino-Mndez I., de Bruijn I., et al. Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clin. Cancer Res. 2017;23(21):6708-20. doi: 10.1158/1078-0432.CCR-17-0544.
  47. Kurian A.W., Ward К.С., Howlader N. Genetic Testing and Results in a Population- Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. J Clin Oncol. 2019;07(15):1005-15. Doi: 10.1200/ JCO.18.01854.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies